Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ZFN-603 + ZFN-758** is a combination of two zinc finger nucleases (ZFNs) designed to target and cleave the E7 oncogene DNA of high-risk human papillomavirus (HPV) types 16 and 18, respectively. Laboratory studies have shown that these agents induce significant cleavage of HPV16 and HPV18 E7 DNA in infected cells, leading to downregulation of E7 expression, restoration of tumor suppressor gene retinoblastoma 1 (RB1), apoptosis, and growth inhibition in HPV-positive cell lines. The intended therapeutic effect is to block the progression of cervical intraepithelial neoplasia (CIN) caused by persistent HPV16 or HPV18 infection[2][8][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZFN-603 + ZFN-758.